GORX Geopharma (MM)

Largo, Fla., April 8, 2008 /PRNewswire-FirstCall/ -- GeoPharma, Inc. (NASDAQ:GORX) announced that the company will present today at the EdgeWater Research Partners Spring Conference being held at the Grand Hyatt in Denver, Colorado at 2:25 MT. "We are thoroughly pleased to have GeoPharma present at the spring conference," said EdgeWater President David Lavigne. "GeoPharma has a unique story with a thriving Manufacturing and Distribution business. We expect further positive developments in their Specialty Pharma business with several antibiotic drugs soon to enter into production. Furthermore, the continued development of their Early Stage Ovarian Cancer Diagnostic Device and the value it may add if approved, has not been factored into their current valuation." EdgeWater Research Partners recently issued a Quarterly update to their Initial Coverage Report on GeoPharma which is currently the featured report on the GeoPharma website. The EdgeWater report and other research reports can be found on the Investor Relations Home Page at http://www.geopharmainc.com/ . ABOUT EDGEWATER RESEARCH PARTNERS LLC: EdgeWater Research Partners LLC. is an independent subscription based micro cap stock research company. Subscribers receives a monthly micro cap stock newsletter, in addition to individual company research reports and updates similar to the one's issued on GeoPharma. Annual subscriptions to EdgeWater Research services are available at http://www.edgewaterresearch.com/ ABOUT GEOPHARMA, INC.: GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing and Distribution divisions, manufacture, package, and distribute generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide. GeoPharma's growth strategy is to capitalize on its research and manufacturing expertise to develop medical devices and high margin generic drug products for niche markets with high barriers to entry. GeoPharma's competitive advantage in these areas is in its ability to navigate the challenges that such market pursuits present effectively. Currently GeoPharma employs nearly 300 people and operates facilities in Florida, Maryland, Pennsylvania, Nevada, Rhode Island, and Texas utilizing over 330,000 Sq. Ft. of office, warehouse, manufacturing and laboratory facilities. For further information visit the GeoPharma website at http://www.geopharmainc.com/. FORWARD-LOOKING STATEMENTS This press release may contain statements, which constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission. DATASOURCE: GeoPharma, Inc. CONTACT: Alexander Nachman, Director of Investor and Media Relations of GeoPharma, Inc., +1-727-471-0850, ext. 243, Web site: http://www.geopharmainc.com/

Copyright